Life sciences and healthcare is the LeverVenture mandate. These pieces cover biotech and gene therapy, diagnostics and precision medicine, medical devices and surgical robotics, digital and mental health, and longevity and neuroscience, written for the companies building them.
The most recent piece leads and every other piece in this category follows it, each with the line that says what it covers. The other categories are one link away.
Medtech and surgical robotics founders face two questions before any capital conversation: the FDA pathway and the reimbursement pathway. This guide walks through both.
By Peleg ChevionEverything else filed under Life Sciences and Healthcare, newest first.
Longevity and neuro science is harder for generalist investors to underwrite. This guide walks founders through the validation, regulatory, and data questions growth-stage capital will ask.
Read this pieceGrowth-stage founders in life sciences, deep tech, and healthtech are increasingly scrutinized on operational infrastructure before investment history. Here's what that means for you.
Read this pieceA tactical breakdown of AI infrastructure decisions for founders in life sciences, digital health, and deep tech — what to own, what to rent, and what to deprioritize.
Read this piecePrecision medicine is five different businesses, not one market. Margin sits with regulatory linkage and proprietary data, not with sequencing throughput.
Read this pieceThe binding constraint on precision oncology isn't the drugs — it's the biomarker test that has to happen first, and often doesn't in time.
Read this pieceDemand was never the constraint in mental health tech. Who pays, through which channel, and whether they renew is what separates durable companies from churn.
Read this pieceAn app is not a clinician. Mental health access is a workforce and licensure problem — task-shifting and interstate compacts expand capacity; booking software does not.
Read this pieceApproval is not the finish line for a gene therapy. Manufacturing, site-of-care access, payment architecture, and durability are separate commercial risks.
Read this pieceThe FDA's predetermined change control plan lets an AI-enabled device keep learning after clearance without refiling for every update. That changes what's investable.
Read this pieceModel accuracy is table stakes. AI diagnostic winners are decided by prospective validation, workflow integration, and who bears liability for a miss.
Read this pieceRural healthcare access is a reimbursement and logistics problem, not a product problem. Broadband, hospital closures, and billing codes set the real ceiling.
Read this pieceWhen the biotech IPO window is shut, capital doesn't disappear — it changes shape. Which financing instrument a company reaches for is itself diligence.
Read this pieceThe first edition of our read on the passage between venture capital and private equity: who is funding it, what it costs, and where the companies that stall in it actually stall.
Free, no form. The findings, the method and every chart that carries one — complete, not a teaser, and the same text that opens the full report.
Sixty-four pages, this first edition, released to a named reader. One form, one reply, and no list you did not ask to be on.
Disagree with something on this page? That is the most useful message we get.
It reaches a Managing Partner directly, with a copy to the team address. No phone tree, no shared inbox, no marketing sequence.
A partner will reply from a named address.